Actively Recruiting
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Led by AstraZeneca · Updated on 2026-04-28
40
Participants Needed
13
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
CONDITIONS
Official Title
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and females 18 years of age or older at consent
- Documented diagnosis of multiple myeloma per IMWG diagnostic criteria
- ECOG performance status of 0 or 1
- Adequate organ and bone marrow function
- For newly diagnosed multiple myeloma (NDMM) in Module 1: No prior anti-myeloma therapy or no more than 2 cycles of induction therapy
- For NDMM in Module 2: Completed 4 to 6 cycles of induction therapy prior to screening
- Classified as high-risk multiple myeloma
- For early relapsed or primary refractory multiple myeloma: Received and failed 1 or 2 lines of anti-myeloma therapy
- Received a proteasome inhibitor and immunomodulatory drug in previous therapy
- Documented progressive disease within 1 year of starting treatment or within 6 months of completing last anti-myeloma therapy, or confirmed progressive disease within 6 months before screening with refractory or non-responsive status
You will not qualify if you...
- Prior treatment with CAR T therapy targeting any antigen
- Known active or prior central nervous system involvement or meningeal signs of multiple myeloma
- Active or history of plasma cell leukemia at screening
- Seropositive for HIV
- Active Hepatitis B infection
- Active Hepatitis C infection
- Serious underlying medical conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Research Site
Phoenix, Arizona, United States, 85054
Withdrawn
2
Research Site
Duarte, California, United States, 91010
Actively Recruiting
3
Research Site
Denver, Colorado, United States, 80218
Actively Recruiting
4
Research Site
Tampa, Florida, United States, 33612
Actively Recruiting
5
Research Site
Atlanta, Georgia, United States, 30322
Actively Recruiting
6
Research Site
Iowa City, Iowa, United States, 52242
Not Yet Recruiting
7
Research Site
Rochester, Minnesota, United States, 55905
Withdrawn
8
Research Site
St Louis, Missouri, United States, 63110
Actively Recruiting
9
Research Site
New York, New York, United States, 10016
Actively Recruiting
10
Research Site
Nashville, Tennessee, United States, 37203
Actively Recruiting
11
Research Site
Dallas, Texas, United States, 75235
Withdrawn
12
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
13
Research Site
Charlottesville, Virginia, United States, 22903
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here